Johnson & Johnson Innovation - JJDC’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Johnson & Johnson Innovation - JJDC’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$5.98M	Hold	1,607,044	–	–	0.61%	12
2021 Q1	$5.56M	Hold	1,607,044	–	–	0.72%	10
2020 Q4	$5.4M	Hold	1,607,044	–	–	0.7%	9
2020 Q3	$5.64M	Hold	1,607,044	–	–	1.14%	10
2020 Q2	$7.39M	Hold	1,607,044	–	–	1.45%	9
2020 Q1	$5.32M	Hold	1,607,044	–	–	2.89%	6
2019 Q4	$9.82M	Buy	+1,607,044	New	+$6.62M	3.54%	5

Other funds holding PHAS

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Johnson & Johnson Innovation - JJDC's PHAS Position: Q2 2021 in Review

Johnson & Johnson Innovation - JJDC held its PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) position steady in Q2 2021 at 1,607,044 shares worth $5.98M. The position accounts for 0.61% of the portfolio, ranked #12.

Johnson & Johnson Innovation - JJDC first reported a position in PHAS in Q4 2019 and has held it in 7 quarters since. The position peaked at $9.82M in Q4 2019. 55 funds tracked by Wall St. Rank hold PHAS as of Q2 2021.

Johnson & Johnson Innovation - JJDC held 1,607,044 shares of PhaseBio Pharmaceuticals, Inc. Common Stock worth $5.98M as of Q2 2021.
Johnson & Johnson Innovation - JJDC left its PhaseBio Pharmaceuticals, Inc. Common Stock share count unchanged in Q2 2021.
PhaseBio Pharmaceuticals, Inc. Common Stock made up 0.61% of Johnson & Johnson Innovation - JJDC's portfolio in Q2 2021, its #12 holding.
Johnson & Johnson Innovation - JJDC first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q4 2019 and has held it in 7 quarters since.
Johnson & Johnson Innovation - JJDC's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $9.82M in Q4 2019.
55 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q2 2021.

Based on Johnson & Johnson Innovation - JJDC's 13F filing for Q2 2021, filed 3 Aug 2021.